secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K
Filed at:   2022-08-02T23:59:59+00:00
Accession:  0001564590-22-027326
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX Q2 revenue $861M +4% reported; EPS $1.56 -33%; cuts FY2022 guidance
-------------------------------------------------------------------------

- Revenue $861M, up 4% reported and 6.5% organic; CAG Diagnostics recurring revenue +4% reported, +7% organic.
- EPS $1.56, down 33% as reported, including $0.72 impact from $80M discrete R&D investments.
- Record Q2 premium instrument placements up 18% YoY; global installed base +15%.
- Updated FY2022 revenue guidance $3,305-$3,385M (3%-5.5% reported, 5.5%-8% organic); EPS $7.77-$8.05.
- U.S. same-store clinical visits declined 3% in Q2 vs +13% prior year; diagnostics revenue +6% same-store.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000156459022027326/0001564590-22-027326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000156459022027326/idxx-8k_20220802.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-027326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer